A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

• Published in: Investigational new drugs 2019-06, Vol.37 (3), p.461-472
• Main Authors: Jimeno, Antonio, Moore, Kathleen N., Gordon, Michael, Chugh, Rashmi, Diamond, Jennifer R., Aljumaily, Raid, Mendelson, David, Kapoun, Ann M., Xu, Lu, Stagg, Robert, Smith, David C.
• Format: Article
• Language: English
• Subjects: Adaptor Proteins, Signal Transducing - antagonists & inhibitors; Adult; Aged; Antibodies; Antibodies, Bispecific - immunology; Antibodies, Bispecific - pharmacokinetics; Antibodies, Bispecific - therapeutic use; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Anticancer properties; Antineoplastic Agents - immunology; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Antitumor activity; Bispecific antibodies; Calcium-Binding Proteins - antagonists & inhibitors; Cancer; Clinical trials; Endometrial cancer; Endometrium; Expansion; Fatigue; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic - drug effects; Growth factors; Headache; Humans; Hypertension; Immunogenicity; Lesions; Male; Maximum Tolerated Dose; Medical research; Medicine; Medicine & Public Health; Middle Aged; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - pathology; Oncology; Outer membrane proteins; Ovarian cancer; Pancreas; Patients; Pharmacodynamics; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Phase I Studies; Prognosis; Pulmonary hypertension; Solid tumors; Studies; Tissue Distribution; Toxicity; Tumors; Uterine cancer; Uterus; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors
• ISSN: 0167-6997; 1573-0646
• DOI: 10.1007/s10637-018-0665-y

Summary Purpose Navicixizumab (OMP-305B83) is a bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor. This Phase 1a trial assessed escalating doses of navicixizumab in refractory solid tumors patients. Design A 3 + 3 dose escalation design was used followed by the treatment of additional patients in an expansion cohort. Study objectives were determination of the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy. Results Sixty-six patients were treated once every 3 weeks in 8 dose-escalation cohorts (0.5, 1, 2.5, 3.5, 5, 7.5, 10, and 12.5 mg/kg) and an expansion cohort (7.5 mg/kg). The median age was 60 years and 68% of the patients were female. The most commonly enrolled tumor types were ovarian (12), colorectal (11) and breast, pancreatic, uterine and endometrial (4 each) cancers. As only 1 dose limiting toxicity occurred, the maximum tolerated dose was not reached, but 7.5 mg/kg was chosen as the dose for the expansion cohort. The treatment related adverse events (≥15% of patients) were hypertension (57.6%), headache (28.8%), fatigue (25.8%), and pulmonary hypertension (18.2%). Pulmonary hypertension was mostly asymptomatic at doses ≤5 mg/kg (6 Gr1, 1 Gr2), but was more severe at higher doses (4 Gr2, 1 Gr3). Navicixizumab’s half-life was 11.4 days and there was a moderate (29%) incidence of anti-drug antibody formation. Four patients (3 ovarian cancer, 1 uterine carcinosarcoma) had a partial response and 17 patients had stable disease. Nineteen patients had a reduction in the size of their target lesions including 7/11 patients with ovarian cancer. Four patients remained on study for >300 days and 2 of these patients were on study for >500 days. Conclusions Navicixizumab can be safely administered with manageable toxicities and these data showed preliminary signs of antitumor activity in multiple tumor types, but was most promising in ovarian cancer. As a result these data justify its continued development in combination Phase 1b clinical trials.